Target intelligence / Profile preview

Flap endonuclease 1 (FEN1)

Target
FEN1
Molecular classification
Enzyme, Structure-specific nuclease, Member of the XPG/RAD2 endonuclease family
01

Overview

Flap endonuclease 1 (FEN1) is a structure-specific nuclease encoded by the FEN1 gene, essential for DNA replication and repair in eukaryotic cells[1][2][3][4]. FEN1 removes 5' overhanging single-stranded DNA “flaps” generated during Okazaki fragment maturation in lagging strand synthesis and is essential in long-patch base excision repair[1][2][3]. It maintains genomic stability, interacting with other repair proteins (e.g., PCNA, APEX1, WRN) to coordinate DNA processing steps[1][2]. FEN1 is a key factor in cancer biology—its inhibition is selectively toxic to tumor cells with homologous recombination repair defects (notably, BRCA1/2-mutant tumors), making it a candidate therapeutic target in oncology[1]. FEN1's catalytic activity and substrate recognition are finely regulated by protein partners and post-translational modifications, and its dysfunction is associated with cancer, chromosomal instability, and disorders of premature aging[2][3][4].

Other names
FEN1Flap structure-specific endonuclease 1hFEN1
02

Mechanism of action

Inhibition of FEN1 results in impaired DNA repair, promoting synthetic lethality in tumor cells deficient in homologous recombination repair pathways (such as those with BRCA1/2 mutations)[1]

03

Biological functions

DNA replicationDNA repairOkazaki fragment maturationLong-patch base excision repairGenome stability maintenance
04

Disease associations

CancerTumorigenesisChromosomal instabilityPremature aging disorders
05

Safety considerations

Genomic instability from excessive FEN1 inhibitionPotential off-target DNA damage in normal cells leading to cytotoxicity and mutagenesis
06

Interacting drugs

Small molecule FEN1 inhibitors (no approved drugs as of 2025, but several investigated pre-clinically for synthetic lethality in BRCA-deficient cancers)[1]
07

Biomarkers

FEN1 expression may serve as a biomarker for DNA repair activity and cancer susceptibility, especially for stratifying BRCA-deficient tumors and monitoring synthetic lethal therapeutic response[1]

Beyond the preview

Go deeper on Flap endonuclease 1 (FEN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flap endonuclease 1 (FEN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call